Cephalon's lestaurtinib fails pivotal trial in leukaemia
This article was originally published in Scrip
Executive Summary
Cephalon's new experimental multi-targeted kinase inhibitor, lestaurtinib (CEP-701), has failed to show a benefit in a pivotal trial in patients with relapsed acute myelogenous leukaemia (AML) expressing FLT3 activating mutations, but experts remained hopeful about the strategy of inhibiting FLT3 in AML.